Kronos Bio Inc
NASDAQ:KRON 4:00:00 PM EDT
| Market Cap (Intraday) | 61.90M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.10 |
| 50-Day MA | $1.15 |
| 200-Day MA | $1.27 |
Kronos Bio Inc Stock, NASDAQ:KRON
1300 So. El Camino Real, Suite 300, San Mateo, California 94402
United States of America
Phone: +1.650.781.5200
Number of Employees: 63
Description
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.